ClinicalTrials.gg
CompletedNCT06462612Updated Jul 24, 2026

Study of Lumateperone in the Treatment of Patients With Bipolar Mania

A Phase 3 interventional study of Lumateperone and Placebo in Bipolar Disorder, Manic, sponsored by Intra-Cellular Therapies, Inc.. Completed at 35 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Bipolar Disorder by Johnson & Johnson — 2 open to participants now, 2 under way, 2 of them phase 3. Bipolar Disorder · Johnson & Johnson.

Enrollment
15th of 36
351 · median 300
Started
2024
with 3 others
Phase 3
28 of 39
2 open now
Registered
38th of 39
by date

Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 15th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2024, is one of 28 in phase 3, and was the 38th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 39 studies in Bipolar Disorder by Johnson & Johnson are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Bipolar Disorder by Johnson & Johnson, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Read the detailed description

The study will be conducted in 3 phases:

  • Screening Period (up to 1 week) during which patient eligibility will be assessed.
  • Double-blind Treatment Period (3 weeks) during which all eligible patients will be randomized to receive lumateperone 42 mg or placebo in 1:1 ratio.
  • Safety Follow-up Period (1 week) during which all patients will return to the clinic for a safety follow-up visit
03

Conditions studied

  • Bipolar Disorder, Manic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written before the initiation of any study specific procedures;
  2. Male or female inpatient, between the ages of 18 and 75 years, inclusive;
  3. Meets the , 5th Edition (DSM 5) criteria for bipolar I disorder with a current episode of mania or mania with mixed features with or without psychotic symptoms, as confirmed by a trained and Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT);
  4. YMRS total score ≥ 20 and a score of at least 4 on two of the following YMRS items: irritability, speech, content, and disruptive/aggressive behavior at Screening and Baseline;
  5. Hospitalized voluntarily before Screening or admitted to inpatient unit at Visit 1 with a primary diagnosis of mania but not > 14 days before Screening. Hospital admission must be a result of the current manic episode.

Exclusion criteria

Exclusion Criteria:

  1. Has a current primary DSM 5 psychiatric diagnosis other than bipolar disorder. These include:

    1. Schizophrenia, schizoaffective disorder, or other psychotic disorders;
    2. Dementia or other cognitive disorders;
    3. Intellectual disability;
    4. Moderate or severe substance use disorder (excluding for nicotine);
  2. Experiencing first manic episode;
  3. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during the course of his/her participation in the study or

    1. At Screening, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening; or
    2. At Screening, the patient has had 1 or more suicidal attempts within 2 years prior to Screening; or
    3. At Baseline, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the C-SSRS since the Screening Visit; or
    4. At Screening or Baseline, scores ≥ 4 on Item 10 (suicidal thoughts) on the rater administered Montgomery-Åsberg Depression Rating Scale (MADRS); or
    5. Considered to be an imminent danger to himself/herself or others.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    Lumateperone 42 mg

    Lumateperone 42 mg capsules

    Drug: Lumateperone

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • Lumateperone 42 mg capsules administered orally, once daily

  • DrugPlacebo

    Matching capsules administered orally, once daily

06

What researchers measure

Primary outcomes

  1. Young Mania Rating Scale (YMRS)

    The YMRS is an 11-item, clinician-administered mania rating scale designed to assess the severity of manic symptoms. Four of the YMRS items are rated on a 0 to 8 scale, with the remaining 7 items rated on a 0 to 4 scale. The total score ranges from 0 to 60 with a higher score indicating increased severity of manic symptoms.

    Time frame: Week 3

Secondary outcomes

  1. Clinical Global Impression Scale-Severity (CGI-S)

    The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Week 3

07

Study locations

35 sites
  • Clinical Site
    Bentonville, Arkansas 72712, United States
  • Clinical Site
    Little Rock, Arkansas 72211, United States
  • Clinical Site
    Anaheim, California 92805, United States
  • Clinical Site
    Cerritos, California 90703, United States
  • Clinical Site
    Orange, California 92868, United States
  • Clinical Site
    Torrance, California 90504, United States
  • Clinical Site
    Hialeah, Florida 33012, United States
  • Clinical Site
    Miami, Florida 33122, United States
  • Clinical Site
    Miami, Florida 33135, United States
  • Clinical Site
    Miami, Florida 33145, United States
  • Clinical Site
    Miami Lakes, Florida 33014, United States
  • Clinical Site
    Miami Lakes, Florida 33016, United States
  • Clinical Site
    Tampa, Florida 33629, United States
  • Clinical Site
    West Palm Beach, Florida 33407, United States
  • Clinical Site
    Atlanta, Georgia 30331, United States
  • Clinical Site
    Stockbridge, Georgia 30281, United States
  • Clinical Site
    Chicago, Illinois 60640, United States
  • Clinical Site
    Chicago, Illinois 60641, United States
  • Clinical Site
    Gaithersburg, Maryland 20877, United States
  • Clinical Site
    Glen Oaks, New York 11004, United States
  • Clinical Site
    Cincinnati, Ohio 45219, United States
  • Clinical Site
    Richardson, Texas 75080, United States
  • Clinical Site
    Burgas, 8000, Bulgaria
  • Clinical Site
    Kazanlak, 6100, Bulgaria
  • Clinical Site
    Plovdiv, 4002, Bulgaria
  • Clinical Site
    Sliven, 8800, Bulgaria
  • Clinical Site
    Sofia, 1431, Bulgaria
  • Clinical Site
    Brasov, 507190, Romania
  • Clinical Site
    Bucharest, 06022, Romania
  • Clinical Site
    Iași, 700282, Romania
  • Clinical Site
    Belgrade, 11000, Serbia
  • Clinical Site
    Kovin, 26220, Serbia
  • Clinical Site
    Kragujevac, 34000, Serbia
  • Clinical Site
    Niš, Serbia
  • Clinical Site
    Novi Kneževac, Serbia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in May 2026, 21 months.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 21 months is below that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 17, 2024
StartActual
Jul 17, 2024
Primary completionActual
May 15, 2026
CompletionActual
May 20, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06462612
Responsible party
Sponsor
First posted
Jun 17, 2024
Start date
Jul 17, 2024
Primary completion
May 15, 2026
Completion
May 20, 2026
Last update
Jul 24, 2026

Study contacts

Intra-Cellular Therapies, Inc. Clinical Trial
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion